Login Register Cart 0
Generic placeholder image

当代肿瘤药物靶点

Editor-in-Chief

ISSN (Print): 1568-0096
ISSN (Online): 1873-5576

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe Translate in English
Case Report

多药协同靶向综合治疗晚期肝细胞癌病例报告及文献复习

卷 24, 期 3, 2024

发表于: 18 September, 2023

页: [368 - 374] 页: 7

弟呕挨: 10.2174/1568009623666230801093031

价格: $65

摘要

背景:一名43岁女性患者在常规筛查中发现肝功能异常，甲胎蛋白异常升高，肝脏占位性病变。病人来我院作进一步诊治。 病例介绍:调查:采用病理染色和免疫组织化学方法，进行实验室检查、肝动脉数字减影血管造影(DSA)、腹部超声检查、磁共振成像(MRI)扫描。诊断:临床诊断:cT3NxM0。巴塞罗那临床肝癌(BCLC)分期:BCLC c期。中国肝癌(CNLC)分期:CNLC IIIa期。 讨论:患者首次住院接受经导管动脉化疗栓塞(TACE)和基于奥沙利铂的肝动脉灌注化疗(HAIC)。然后，根据FOLFOX对第二次和第三次住院患者进行HAIC。在前三种治疗中，还通过微导管将卡瑞利珠和溶瘤病毒注射到肝癌中。第四次入院时，患者各项指标好转，肿瘤缩小。此外，由于患者最初几次出现不良反应，我们暂停了奥沙利铂和溶瘤病毒的治疗。手术治疗前，乐伐替尼在整个治疗过程中使用。在第五次入院时，患者接受了肝癌切除术。 结论:证实了多种联合治疗的价值，可为不能手术切除的晚期肝癌患者提供指导。

关键词: 晚期肝癌，不可切除，TACE, HAIC，联合治疗，化疗。

« Previous
[1]
Bruix, J; Han, KH; Gores, G; Llovet, JM; Mazzaferro, V Liver cancer: Approaching a personalized care. J Hepatol., 2015, 62(1), S144-1456.
[2]
Bruix, J; Sherman, M Management of hepatocellular carcinoma: An update. Hepatology., 2011, 53(3), 1020-1022.
[http://dx.doi.org/10.1002/hep.24199]
[3]
Zhou, J; Sun, HC; Wang, Z; Cong, WM; Wang, JH; Zeng, MS Guidelines for diagnosis and treatment of primary liver cancer in China. Liver Cancer., 2018, 7(3), 235-260.
[4]
Zhou, J; Sun, H; Wang, Z; Cong, W; Wang, J; Zeng, M Guidelines for the diagnosis and treatment of hepatocellular carcinoma. Liver Cancer., 2020, 9(6), 682-720.
[5]
Chacko, S; Samanta, S. Hepatocellular carcinoma: A life-threatening disease. Biomed Pharmacother., 2016, 84, 1679-1688.
[http://dx.doi.org/10.1016/j.biopha.2016.10.078]
[6]
Villanueva, A. Hepatocellular carcinoma. N Engl J Med., 2019, 380(15), 1450-1462.
[http://dx.doi.org/10.1056/NEJMra1713263]
[7]
Faivre, S; Rimassa, L; Finn, RS Molecular therapies for HCC: Looking outside the box J Hepatol., 2020, 72(2), 342-352.
[8]
EASL Clinical Practice Guidelines. Management of hepatocellular carcinoma. J Hepatol., 2018, 69(1), 182-236.
[9]
Yau, T; Tang, VY; Yao, TJ; Fan, ST; Lo, CM; Poon, RT Development of hong kong liver cancer staging system with treatment stratification for patients with hepatocellular carcinoma. Gastroenterology., 2014, 146(7), 1691-1700.
[http://dx.doi.org/10.1053/j.gastro.2014.02.032]
[10]
Park, JW; Chen, M; Colombo, M; Roberts, LR; Schwartz, M; Chen, PJ Global patterns of hepatocellular carcinoma management from diagnosis to death: The bridge study. Liver Int., 2015, 35(9), 2155-2166.
[http://dx.doi.org/10.1111/liv.12818]
[11]
Jiang, H; Meng, Q; Tan, H; Pan, S; Sun, B; Xu, R Antiangiogenic therapy enhances the efficacy of transcatheter arterial embolization for hepatocellular carcinomas. Int J Cancer., 2007, 121(2), 416-424.
[http://dx.doi.org/10.1002/ijc.22655]
[12]
Kudo, M.; Ueshima, K.; Ikeda, M.; Torimura, T.; Tanabe, N.; Aikata, H.; Izumi, N.; Yamasaki, T.; Nojiri, S.; Hino, K.; Tsumura, H.; Kuzuya, T.; Isoda, N.; Yasui, K.; Aino, H.; Ido, A.; Kawabe, N.; Nakao, K.; Wada, Y.; Yokosuka, O.; Yoshimura, K.; Okusaka, T.; Furuse, J.; Kokudo, N.; Okita, K.; Johnson, P.J.; Arai, Y. Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial. Gut., 2020, 69(8), 1492-1501.
[http://dx.doi.org/10.1136/gutjnl-2019-318934] [PMID: 31801872]
[13]
He, M; Li, Q; Zou, R; Shen, J; Fang, W; Tan, G Sorafenib plus hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin vs. sorafenib alone for hepatocellular carcinoma with portal vein invasion. JAMA Oncol., 2019, 5(7), 953.
[14]
Lyu, N; Kong, Y; Mu, L; Lin, Y; Li, J; Liu, Y Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma. J Hepatol., 2018, 69(1), 60-69.
[15]
Kudo, M.; Matsui, O.; Izumi, N.; Iijima, H.; Kadoya, M.; Imai, Y.; Okusaka, T.; Miyayama, S.; Tsuchiya, K.; Ueshima, K.; Hiraoka, A.; Ikeda, M.; Ogasawara, S.; Yamashita, T.; Minami, T.; Yamakado, K. JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 Update by the liver cancer study group of Japan. Liver Cancer., 2014, 3(3-4), 458-468.
[http://dx.doi.org/10.1159/000343875] [PMID: 26280007]
[16]
Li, Q.J.; He, M.K.; Chen, H.W.; Fang, W.Q.; Zhou, Y.M.; Xu, L. Hepatic arterial infusion of oxaliplatin, fluorouracil, and leucovorin versus transarterial chemoembolization for large hepatocellular carcinoma: A randomized phase III Trial. J. Clin. Oncol., 2021, 2021, O2100608.
[PMID: 34648352]
[17]
Lyu, N; Lin, Y; Kong, Y; Zhang, Z; Liu, L; Zheng, L FOXAI: A phase II trial evaluating the efficacy and safety of hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin for advanced hepatocellular carcinoma GUT.Letter; Comment, 2018, 67(2), 395-396.
[18]
Kudo, M; Finn, RS; Qin, S; Han, KH; Ikeda, K; Piscaglia, F Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet., 2018, 391(10126), 1163-1173.
[http://dx.doi.org/10.1016/S0140-6736(18)30207-1]
[19]
Qin, S.; Ren, Z.; Meng, Z.; Chen, Z.; Chai, X.; Xiong, J.; Bai, Y.; Yang, L.; Zhu, H.; Fang, W.; Lin, X.; Chen, X.; Li, E.; Wang, L.; Chen, C.; Zou, J. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: A multicentre, open-label, parallel-group, randomised, phase 2 trial. Lancet Oncol., 2020, 21(4), 571-580.
[http://dx.doi.org/10.1016/S1470-2045(20)30011-5] [PMID: 32112738]
[20]
Wang, K.; Wang, H.; Lv, Y.; Liu, H.; Liu, J.; Zhang, Y. Camrelizumab combined with lenvatinib in the treatment of gastric cancer with liver metastasis: A case report. Ann. Palliat. Med., 2021, 10(1), 803-809.
[http://dx.doi.org/10.21037/apm-20-2572] [PMID: 33545802]
[21]
Wei, F; Huang, Q; He, J; Luo, L; Zeng, Y. Lenvatinib plus camrelizumab versus lenvatinib monotherapy as post-progression treatment for advanced hepatocellular carcinoma: A short-term prognostic study. Cancer Manag Res., 2021, 13, 4233-4240.
[http://dx.doi.org/10.2147/CMAR.S304820]
[22]
Russell, SJ; Peng, KW; Bell, JC Oncolytic virotherapy. Nat Biotechnol., 2012, 30(7), 658-670.
[23]
Kaufman, HL; Kohlhapp, FJ; Zloza, A Oncolytic viruses: A new class of immunotherapy drugs. NAt Rev Drug Discov., 2015, 14(9), 642-662.
[http://dx.doi.org/10.1038/nrd4663]
[24]
Bommareddy, PK; Shettigar, M; Kaufman, HL Integrating oncolytic viruses in combination cancer immunotherapy. Nat Rev Immunol., 2018, 18(8), 498-513.
[http://dx.doi.org/10.1038/s41577-018-0014-6]
[25]
Lawler, SE; Speranza, MC; Cho, CF; Chiocca, EA Oncolytic viruses in cancer treatment: A review. JAMA ONCOL., 2017, 3(6), 841-849.
[http://dx.doi.org/10.1001/jamaoncol.2016.2064]
[26]
Boozari, B; Mundt, B; Woller, N; Struver, N; Gurlevik, E; Schache, P Antitumoural immunity by virus-mediated immunogenic apoptosis inhibits metastatic growth of hepatocellular carcinoma. GUT., 2010, 59(10), 1416-1426.
[http://dx.doi.org/10.1136/gut.2009.196519]
[27]
Heo, J; Reid, T; Ruo, L; Breitbach, CJ; Rose, S; Bloomston, M Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer Nat Med., 2013, 19(3), 329-336.
[28]
Zhang, H; Li, K; Lin, Y; Xing, F; Xiao, X; Cai, J Targeting VCP enhances anticancer activity of oncolytic virus M1 in hepatocellular carcinoma. Sci Transl Med., 2017, 9(404), eaam7996.
[http://dx.doi.org/10.1126/scitranslmed.aam7996]
[29]
He, CB; Lao, XM; Lin, XJ Transarterial chemoembolization combined with recombinant human adenovirus type 5 h101 prolongs overall survival of patients with intermediate to advanced hepatocellular carcinoma: A prognostic nomogram study Chin J Cancer., 2017, 36(1), 59.
[30]
Lin, XJ; Li, QJ; Lao, XM; Yang, H; Li, SP Transarterial injection of recombinant human type-5 adenovirus H101 in combination with transarterial chemoembolization (TACE) improves overall and progressive-free survival in unresectable hepatocellular carcinoma (HCC). BMC CANCER., 2015, 15, 707.

Rights & Permissions Print Cite
Article Metrics
21
2
© 2024 Bentham Science Publishers | Privacy Policy